Exicure, Inc. (XCUR)
 NASDAQ: XCUR · Real-Time Price · USD
 4.440
 -0.020 (-0.45%)
  At close: Oct 30, 2025, 4:00 PM EDT
4.420
 -0.020 (-0.45%)
  After-hours: Oct 30, 2025, 7:35 PM EDT
Exicure Employees
Exicure had 7 employees as of December 31, 2024. The number of employees increased by 1 or 16.67% compared to the previous year.
Employees 
 7
Change (1Y) 
 1
Growth (1Y) 
 16.67%
Revenue / Employee 
 n/a
Profits / Employee 
 -$1,126,143
Market Cap 
28.05M
Employees Chart
Employees History
| Date | Employees | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 7 | 1 | 16.67% | 
| Dec 31, 2023 | 6 | -7 | -53.85% | 
| Dec 31, 2022 | 13 | -34 | -72.34% | 
| Dec 31, 2021 | 47 | -16 | -25.40% | 
| Dec 31, 2020 | 63 | 34 | 117.24% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Related Stocks
| Company Name | Employees | 
|---|---|
| UnitedHealth Group | 400,000 | 
| Johnson & Johnson | 138,100 | 
| Thermo Fisher Scientific | 125,000 | 
| Abbott Laboratories | 114,000 | 
| AstraZeneca | 92,900 | 
| Novo Nordisk | 77,349 | 
| Novartis AG | 75,883 | 
| Merck & Co. | 75,000 | 
XCUR News
- 8 days ago - Halper Sadeh LLC Encourages Exicure, Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
- 24 days ago - Exicure Highlights Recent Achievements and Near-term Strategic Priorities - GlobeNewsWire
- 2 months ago - Exicure, Inc. Reports Second Quarter 2025 Financial Results - Business Wire
- 3 months ago - Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements - Business Wire
- 3 months ago - Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant - Business Wire
- 4 months ago - Exicure, Inc. Reports First Quarter 2025 Financial Results - Business Wire
- 5 months ago - Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q - Business Wire
- 6 months ago - Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant - Business Wire